If your university team or Clinical Trials Unit (CTU) is at full capacity and you’re struggling to get your trial off the ground, we’re here to help. Our team has extensive experience working with NHS and University teams in phase I, phase II, phase III and Phase IV trials (IMP and Medical Devices) across a broad range of therapeutic areas.
We understand there is a lot to navigate when you’re approaching the clinical trial stage of your research journey. We’re here to help from the early stage, even before your funding has come through and at no extra cost. We can work alongside your Translational Research Office (TRO), if applicable, to provide guidance on grant applications, protocol development and resource requirements in order to achieve the best outcome for your trial. Our flexible service model means we can dovetail our services with your available resources making it an efficient and effective partnership.
At PHARMExcel, we foster strong, collaborative relationships with our sponsors and sites ensuring proactive communication and a firm commitment to understanding your needs. As we are a smaller UK CRO, the team introduced during initial interactions remains consistent and accessible throughout your project, fostering stability and accountability for the trial.
"I have worked with Yvanne Enever and the PHARMExcel team for several years on a complex, multicentre Phase 1 vaccine study. I have found them be efficient, highly professional while being accommodating and very supportive. I have worked with other clinical trial research organisations on similar studies and PHARMExcel have been by far the most effective in achieving targets and the easiest to work with on a day to day basis. "
Dr Kim Orchard, Senior Lecturer and Consultant Haematologist, University Hospital Southampton NHSFT
"Yvanne and her team at PHARMExcel are the best team I’ve worked with in liver-related clinical trials. They are talented and committed individuals with great expertise in the regulatory landscape as well as delivery of clinical trials. Highly recommended!"
Dr Gautam Mehta, Hepatologist and Principal Investigator, University College London
"It has been a pleasure working with Yvanne and the team. PHARMExcel have been able to work with our clinical research teams to provide bespoke support for a number of trials, including phase 1 studies: the personal approach and attention to detail have given us confidence to ensure patient safety and manage the risks of the Trust acting as Sponsor in particular for the early phase trials."
Karen Underwood & Professor Saul Faust, Sponsor, University Hospital Southampton NHSFT
"PHARMExcel are very interactive and excellent in communicating with clinical teams. They have a thorough understanding of the regulatory requirements for managing GCP compliant clinical trials. I have no hesitation in recommending them as a CRO."
Dr Kim Orchard, Senior Lecturer and Consultant Haematologist University Hospital Southampton NHS FT
"PHARMExcel’s passion for their projects, the professionalism shown by the team, combined with direct access to the CEO sets PHARMExcel apart from other CROs."
Sponsor
"The support from PHARMexcel has been extremely high quality. This includes all aspects trial development, management and monitoring, that was also evidenced by a recent sponsor audit. We look forward to working with PHARMexcel going forwards."
Tom Fletcher, CST-6 Candidate Chief Investigator, Director Global Health Trials Unit,
Liverpool School of Tropical Medicine
Learn more about our successful CRO-Academic partnerships
CARDIOLOGY
A phase II/III, randomized trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy.
Sponsor – NHS University College London
ONCOLOGY
A phase I/IIa study of targeted radiotherapy alone for stem cell transplant conditioning in Systemic AL Amyloidosis.
Sponsor – University Hospital Southampton
RARE DISEASE
A recombinant human monoclonal antibody treatment option, Secukinumab, for patients with Bechet’s Syndrome, a rare chronic, auto-inflammatory, multisystem disorder. A phase II study.
Sponsor – NHS Liverpool University Hospitals
INFECTIOUS DISEASES
A phase I/II study for an antiviral treatment, Favipiravir, a potential treatment option for hospitalised patients with severe Covid-19 disease.
Sponsor – University of Liverpool
CARDIOLOGY
A phase I study to assess the safety and feasibility of clinical grade Wharton’s jelly-derived mesenchymal stromal cells seeded valve-conduit for right ventricular outflow tract reconstruction in patients with Tetralogy of Fallot/Pulmonary Atresia.
Sponsor – University Hospitals Bristol NHS FT
INFECTIOUS DISEASES
A phase I safety, immunogenicity and dose escalation study of the candidate pan-Sarbeco Coronavirus vaccine pEVAC_PS in SARS-CoV-2 immunised UK healthy adult volunteers.
Sponsor – University Hospital Southampton
OPHTHALMOLOGY
Phase I Novel Treatment
One of the largest clinical studies of patients with Birdshot Uveitis (eye disease) in the UK running at Moorfields Eye Hospital and University Hospital Birmingham.
GENE TRANSFER
A UK/USA Phase I open label dose-escalation of a self-complementary adeno-associated viral vector for gene transfer in subjects with Haemophilia B
Sponsor – University College London
